USPTO serial 88057861
AIONCO
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- REINHART, MEGHAN M
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with AIONCO?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Milbrae, CA
Milbrae, CA
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Andrew J. Gray IV
Andrew J. Gray IV Morgan, Lewis & Bockius LLP1400 Page Mill RoadPalo Alto, CA 94304UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Medical testing products, namely, modified immune cells; Medical testing products, namely, modified immune cells for use in connection with various cancers with genetic treatments | ACTIVE | — |
| 009 | Downloadable software and mobile applications for genetic assessment and identification of cancer, cancer ailments, and cancer mutations for scientific, medical, diagnostic, treatment, and research purposes, for creating local databases of genomic sequences, cancer ailments, and cancer mutations for tracking, matching, searching, testing, aggregating, researching, and diagnosing cancer, cancer ailments, and cancer mutations, for creating, accessing, and using online databases of genomic sequences, cancer ailments, and cancer mutations for tracking, matching, searching, testing, aggregating, researching, and diagnosing cancer, cancer ailments, and cancer mutations, for recording, analyzing, storing, manipulating and organizing genetic and molecular data, and for providing access to multiple online databases that contain aggregated results of molecular biology testing and genotyping; medical testing products, namely, downloadable vaccination test forms | ACTIVE | — |
| 010 | Medical testing and treatment products in the form of treatment therapies, namely, apparatus for medical diagnosis, drug delivery apparatus and genetic delivery apparatus all for various cancers with genetic treatments and specimen collection tubes and containers for collecting patient specimens, namely, blood, urine, saliva, and tissue, for genomic sequencing and for detection of gene mutations, gene expression profiles or other molecular indicators or markers associated with cancer or risk of developing cancer; Medical testing and treatment product kits containing blood specimen collection tubes and containers for collecting patient blood specimens for genomic sequencing and detection of gene mutations, gene expression profiles or other molecular indicators or markers associated with cancer or risk of developing cancer modified immune cells and treatment therapies, and also containing modified immune cells, treatment therapies, test forms, mailing materials and user information inserts | ACTIVE | — |
| 016 | Medical testing and treatment products, namely, printed test forms and printed user information inserts for medical products; Medical testing products, namely, printed vaccination test forms | ACTIVE | — |
| 042 | Providing online non-downloadable software and software programs for genetic assessment and identification of cancer, cancer ailments, and cancer mutations for scientific, medical, diagnostic, treatment, and research purposes, for creating online databases of genomic sequences, cancer ailments, and cancer mutations for tracking, matching, searching, testing, aggregating, researching, and diagnosing cancer, cancer ailments, and cancer mutations, for creating, accessing, and using online databases of genomic sequences, cancer ailments, and cancer mutations for tracking, matching, searching, testing, aggregating, researching, and diagnosing cancer, cancer ailments, and cancer mutations, for recording, analyzing, storing, manipulating and organizing genetic and molecular data, and for providing access to multiple online databases that contain aggregated results of molecular biology testing and genotyping | ACTIVE | — |
| 044 | Providing medical diagnostic and treatment services, namely, tumor detection in the form of a liquid biopsy; medical diagnostic and treatment services in the nature of tumor analysis, diagnosis, and identification in the form of sequenced tissue identification, and tumor medical treatment therapy in the form of identification of appropriate combination of mutations for targeted cancers and identification of appropriate treatments targeted for those combination of mutations via modified T-Cells in the form of other treatments to inhibit expressions of those combination of mutations and to modify one or more of the mutations in the combination | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Gene Lee
- Other trademarks owned by Gene Lee
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 010
- Other trademarks in Class 016
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named AIONCO
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 7, 2022 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Nov 7, 2022 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Apr 13, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Apr 12, 2022 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Apr 1, 2022 | EXT5 | SOU EXTENSION 5 FILED | — |
| Apr 1, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 30, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 28, 2021 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Sep 28, 2021 | EXT4 | SOU EXTENSION 4 FILED | — |
| Sep 28, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 2, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 31, 2021 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Mar 31, 2021 | EXT3 | SOU EXTENSION 3 FILED | — |
| Mar 31, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 2, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 30, 2020 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Sep 30, 2020 | EXT2 | SOU EXTENSION 2 FILED | — |
| Sep 30, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 3, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Apr 2, 2020 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Apr 2, 2020 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Apr 2, 2020 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Mar 31, 2020 | EXT1 | SOU EXTENSION 1 FILED | — |
| Mar 31, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 31, 2020 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Mar 31, 2020 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 31, 2020 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 31, 2020 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Mar 31, 2020 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Oct 1, 2019 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Aug 6, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 6, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 17, 2019 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 3, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 3, 2019 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jul 3, 2019 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jul 3, 2019 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jul 3, 2019 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jul 1, 2019 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Jun 18, 2019 | PBCR | WITHDRAWN FROM PUB - OG REVIEW QUERY | — |
| May 31, 2019 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| May 30, 2019 | ALIE | ASSIGNED TO LIE | — |
| May 16, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 16, 2019 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| May 16, 2019 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| May 16, 2019 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| May 16, 2019 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Apr 30, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 29, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 29, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 26, 2018 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 26, 2018 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 26, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 15, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 3, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 2, 2018 | NWAP | NEW APPLICATION ENTERED | — |